Business
Valerio Therapeutics Announces the Launch of InVimmune, a New Company Dedicated to Developing Differentiated in Vivo Cell Therapy Approaches
VILLEJUIF, France, May 04, 2026--Regulatory News: Valerio Therapeutics (FR0010095596 – ALVIO), a biotechnology company specializing in the development of technology platforms dedicated to the targeted delivery of innovative therapies (the "Company"), today announces the launch of InVimmune, a new company dedicated to developing differentiated in vivo cell therapy approaches with potential applications across oncology, fibrosis, autoimmune diseases and additional indications. InVimmune’s first in
About this update from Valerio Therapeutics
[{"type":"text","content":"VILLEJUIF, France, May 04, 2026--(BUSINESS WIRE)--Regulatory News:","length":66,"tagName":"p"},{"type":"text","content":"Valerio Therapeutics (FR0010095596 – ALVIO), a biotechnology company specializing in the development of technology platforms dedicated to the targeted delivery of innovative therapies (the "Company"), today announces the launch of InVimmune, a new company dedicated to developing differentiated in vivo cell therapy approaches with potential applications across oncology, fibrosis, autoimmune diseases and additional indications. InVimmune’s first indication is in oncology, addressing an area of high unmet medical need.","length":531,"tagName":"p"},{"type":"text","content":""Through InVimmune, we are adding a new strategic pillar to Valerio and expanding the reach of our platform into in vivo cell therapy. Our differentiated approach has the potential to be applied across several therapeutic areas, including oncology, fibrosis and autoimmune diseases, with a first indication in oncology where unmet medical need remains high. We continue to strengthen our team and broaden the network of experts surrounding the Company to accelerate the development of our technologies and pipeline. We believe that the quality of our talent, combined with the exceptional scientific advisors supporting Valerio and InVimmune, provides a strong foundation to execute our strategy and deliver on our ambitions." said Julien Miara, Chief Executive Officer of the Company.","length":795,"tagName":"p"},{"type":"text","content":"InVimmune has been established to extend the reach of Valerio’s technology platforms into in vivo cell therapy through a novel immune reprogramming approach. InVimmune will leverage Valerio’s proprietary single-domain antibody platform together with targeted-delivery capabilities to develop differentiated programs across multiple therapeutic areas, with an initial focus on oncology.To support InVimmune’s first oncology program, Valerio has established a dedicated Oncology Scientific Advisory Board, chaired by Professor Eric Vivier. The Board also includes Frederick Ramsdell, PhD, 2025 Nobel Prize in Physiology or Medicine laureate and Chair of the Scientific Advisory Board at Sonoma Biotherapeutics; Alan Korman, PhD, Chief Scientific Officer and Board Member at BlueSphere Bio; Matteo Iannacone, MD, P...